| Literature DB >> 26853749 |
Christian Schlein1, Saswata Talukdar2, Markus Heine1, Alexander W Fischer1, Lucia M Krott1, Stefan K Nilsson1, Martin B Brenner2, Joerg Heeren1, Ludger Scheja3.
Abstract
FGF21 decreases plasma triglycerides (TGs) in rodents and humans; however, the underlying mechanism or mechanisms are unclear. In the present study, we examined the role of FGF21 in production and disposal of TG-rich lipoproteins (TRLs) in mice. Treatment with pharmacological doses of FGF21 acutely reduced plasma non-esterified fatty acids (NEFAs), liver TG content, and VLDL-TG secretion. In addition, metabolic turnover studies revealed that FGF21 facilitated the catabolism of TRL in white adipose tissue (WAT) and brown adipose tissue (BAT). FGF21-dependent TRL processing was strongly attenuated in CD36-deficient mice and transgenic mice lacking lipoprotein lipase in adipose tissues. Insulin resistance in diet-induced obese and ob/ob mice shifted FGF21 responses from WAT toward energy-combusting BAT. In conclusion, FGF21 lowers plasma TGs through a dual mechanism: first, by reducing NEFA plasma levels and consequently hepatic VLDL lipidation and, second, by increasing CD36 and LPL-dependent TRL disposal in WAT and BAT.Entities:
Mesh：
Substances：
Year: 2016 PMID： 26853749 DOI： 10.1016/j.cmet.2016.01.006
Source DB: PubMed Journal: Cell Metab ISSN： 1550-4131 Impact factor: 27.287